HUMA Quote, Financials, Valuation and Earnings

Bio-Path Holdings has a net margin of -- compared to Humacyte's net margin of --. Humacyte's return on equity of -- beat Bio-Path Holdings's return on equity of --.

Humacyte has a consensus price target of $13.71, signalling upside risk potential of 168.91%. On the other hand Bio-Path Holdings has an analysts' consensus of -- which suggests that it could grow by 934.48%. Given that Bio-Path Holdings has higher upside potential than Humacyte, analysts believe Bio-Path Holdings is more attractive than Humacyte.

Humacyte has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Bio-Path Holdings has a beta of 0.083, suggesting its less volatile than the S&P 500 by 91.683%.

Humacyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bio-Path Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Humacyte pays -- of its earnings as a dividend. Bio-Path Holdings pays out -- of its earnings as a dividend.

Humacyte quarterly revenues are --, which are smaller than Bio-Path Holdings quarterly revenues of --. Humacyte's net income of -$39.2M is lower than Bio-Path Holdings's net income of -$2.1M. Notably, Humacyte's price-to-earnings ratio is -- while Bio-Path Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Humacyte is -- versus -- for Bio-Path Holdings. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Humacyte's net margin of -49.65%. Humacyte's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Humacyte has a consensus price target of $13.71, signalling upside risk potential of 168.91%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 503.14%. Given that NovaBay Pharmaceuticals has higher upside potential than Humacyte, analysts believe NovaBay Pharmaceuticals is more attractive than Humacyte.

Humacyte has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.

Humacyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Humacyte pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Humacyte quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Humacyte's net income of -$39.2M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Humacyte's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Humacyte is -- versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

PACS Group has a net margin of -- compared to Humacyte's net margin of -1.11%. Humacyte's return on equity of -- beat PACS Group's return on equity of --.

Humacyte has a consensus price target of $13.71, signalling upside risk potential of 168.91%. On the other hand PACS Group has an analysts' consensus of $34.83 which suggests that it could grow by 160.92%. Given that Humacyte has higher upside potential than PACS Group, analysts believe Humacyte is more attractive than PACS Group.

Humacyte has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PACS Group has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Humacyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PACS Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Humacyte pays -- of its earnings as a dividend. PACS Group pays out 71.23% of its earnings as a dividend. PACS Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Humacyte quarterly revenues are --, which are smaller than PACS Group quarterly revenues of $981.8M. Humacyte's net income of -$39.2M is lower than PACS Group's net income of -$10.9M. Notably, Humacyte's price-to-earnings ratio is -- while PACS Group's PE ratio is 20.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Humacyte is -- versus 0.59x for PACS Group. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Humacyte's net margin of -2357.27%. Humacyte's return on equity of -- beat Palatin Technologies's return on equity of --.

Humacyte has a consensus price target of $13.71, signalling upside risk potential of 168.91%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1140.88%. Given that Palatin Technologies has higher upside potential than Humacyte, analysts believe Palatin Technologies is more attractive than Humacyte.

Humacyte has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.929%.

Humacyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Humacyte pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Humacyte quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Humacyte's net income of -$39.2M is lower than Palatin Technologies's net income of -$7.8M. Notably, Humacyte's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Humacyte is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.